Clinical Trials Logo

Clinical Trial Summary

Renal transplantation is the best option among the end-stage renal disease (ESRD) treatment alternatives, It is also relatively less expensive than dialysis. Allograft rejection is a major issue in kidney transplantation. Rejection is classified as acute or chronic, cellular or antibody-mediated.Children with kidney transplants require life-long immunosuppressive therapy to prevent rejection of the allograft


Clinical Trial Description

The most common medication regimen in the United States includes the combination of corticosteroid (eg, prednisone), a calcineurin inhibitor (or CNI, most commonly tacrolimus), and an antimetabolite such as mycophenolate mofetil (MMF). Cyclosporine and azathioprine are less commonly used for maintenance immunosuppression Tacrolimus level is a main maintenance immunosuppressant in kidney transplantation .In the early days of posttransplant period, hematocrit concentrations are generally low and increase significantly as patient recovers. Because tacrolimus binds strongly to erythrocytes in systemic circulation, the effect of hematocrit on distribution of tacrolimus is important for the methods used to measure tacrolimus concentrations ,hematocrit correction could be a step towards improvement of tacrolimus dose individualization Thearputic drug monitoring of MPA has been proposed to optimize drug dosage avoiding potential hematologic and digestive side effects .MPA monitoring is generally based on the determination of the plasma MPA trough concentration (C0) . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04292418
Study type Observational
Source Assiut University
Contact Aya Khalifa, master degree
Phone 00201016228446
Email dr.ayaahmedkhlifa@gmail.com
Status Not yet recruiting
Phase
Start date May 1, 2020
Completion date October 1, 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04166149 - Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA
Active, not recruiting NCT05483725 - Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
Recruiting NCT03134625 - Metabolite Biomarkers Related to Acute Rejection in Kidney Transplantation
Completed NCT03317925 - Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK) N/A